“`html

Bexicaserin Shows Promise ⁣in‍ Long-Term ⁢treatment of Severe ⁢Epilepsy

Published: 2026/01/15 ‍20:02:40

New long-term ‍data presented at the ⁤American ⁢Epilepsy Society (AES) Congress in December 2025 indicates that‍ bexicaserin (LP352), an investigational drug ‍developed by Lundbeck, continues to demonstrate efficacy⁤ in reducing⁢ seizure frequency‍ in patients⁣ with severe ⁣epilepsy⁤ associated with epileptic and developmental encephalopathies (EED). This offers ⁤a potential new avenue for⁢ treatment in a population with limited options.

Understanding Epileptic and Developmental Encephalopathies (EED)

Epileptic and developmental encephalopathies (EED) are a group of severe and rare epilepsies that typically begin in infancy⁢ or early childhood.These conditions are characterized by frequent, tough-to-control seizures and ⁤frequently enough accompanied by intellectual ‍or‍ developmental disabilities. Becuase ⁣of these⁢ complex challenges, individuals with EED and ⁣their caregivers often face important ‍burdens.